Retatrutide 10mg

Triple GIP/GLP-1/Glucagon Receptor Agonist for Revolutionary Metabolic Research

Retatrutide 10mg provides pharmaceutical-grade triple incretin agonist for researchers investigating next-generation metabolic regulation, unprecedented weight management mechanisms, and synergistic multi-receptor activation. This affordable starter supply supports initial dose-finding studies, protocol optimization, and exploration of triple agonist biology that surpasses dual-agonist approaches in metabolic efficacy and represents the cutting edge of incretin-based research.

Research Applications & Mechanisms

• Triple Receptor Synergy Studies: Investigate synergistic GIP, GLP-1, and glucagon receptor co-activation, complementary signaling pathway integration, multi-tissue metabolic coordination, and unprecedented metabolic outcomes beyond dual-agonist approaches
• Unprecedented Weight Reduction Research: Examine 24-28% body weight loss potential, maximal adiposity reduction, sustained weight loss without plateau, and weight management efficacy approaching bariatric surgery outcomes
• Glucagon-Mediated Energy Expenditure: Study glucagon receptor activation effects on hepatic glucose production, lipolysis enhancement, energy expenditure amplification, thermogenesis activation, and metabolic rate optimization unique to triple agonism
• Enhanced Glycemic Control & Beta-Cell Function: Assess superior HbA1c reduction, glucose-dependent triple hormone secretion modulation, beta-cell preservation, and diabetes intervention exceeding dual-agonist efficacy
• Hepatic Metabolic Transformation: Investigate glucagon-mediated hepatic fat oxidation, NASH/NAFLD resolution, liver enzyme normalization, and hepatic metabolic health superior to GIP/GLP-1 dual agonism
• Cardiovascular & Lipid Optimization: Explore comprehensive cardiovascular risk reduction, triglyceride lowering, HDL elevation, and multi-factorial metabolic health improvement
• Multi-Organ Metabolic Coordination: Study coordinated metabolic effects across pancreas, liver, adipose tissue, skeletal muscle, brain, and cardiovascular system in metabolic syndrome models

Technical Specifications

• Purity: ≥98% 
• Mechanism: Triple GIP/GLP-1/Glucagon receptor agonist with balanced potency
• Molecular Weight: ~5,960 Da
• Form: Lyophilized white to off-white sterile powder
• Half-Life: ~6-7 days (extended-release via fatty acid modification)
• Solubility: Water-soluble; reconstitute in bacteriostatic water (pH 7.0-7.4 optimal)
• Storage: 2-8°C refrigerated; protect from light and freezing
• Stability: Stable for 24 months refrigerated; reconstituted solutions stable 28 days at 2-8°C
• Reconstitution: Add 2mL bacteriostatic water for 5mg/mL concentration
• Price per vial.
• Free shipping.
• All sales final.

Ideal Research Scenarios

The 10mg affordable starter supply is optimized for laboratories conducting preliminary triple agonist studies, dose-response optimization, comparative efficacy trials versus dual agonists, or cost-effective exploration of next-generation metabolic peptide pharmacology representing the future of obesity and diabetes research.

Why Retatrutide Represents the Future of Metabolic Research

Retatrutide's triple GIP/GLP-1/Glucagon agonism represents the most advanced incretin-based approach to date, adding glucagon receptor activation to the proven benefits of dual GIP/GLP-1 agonism. While dual agonists like Tirzepatide achieve 20-25% weight loss, Retatrutide's addition of glucagon signaling—which enhances hepatic fat oxidation, increases energy expenditure, and amplifies lipolysis—produces weight loss approaching 28% in clinical trials. This unprecedented efficacy, rivaling bariatric surgery outcomes through pharmacological intervention alone, makes Retatrutide essential for researchers investigating the limits of metabolic intervention, multi-receptor pharmacology, and the future of obesity therapeutics.

For research use only. Not for human consumption, therapeutic application, or weight management.